Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion

Exclusion Criteria

• •1. Subjects with macular edema secondary to diabetic retinopathy without concomitant proliferative diabetic retinopathy.
• •2. Subjects with cataract or other media opacities impairing adequate visualization of the retina to the extent that good quality images are impossible.
• •3. Presence of any substantial ocular disease (other than diabetic retinopathy or central retinal vein occlusion) that may compromise vision in the study eye and /or confound interpretation of the data; e.g. substantial cataracts, advanced glaucoma, optic neuritis, optic neuropathy or atrophy, marked macular atrophy, history of retinal detachment, uveitis, viral or other forms of chorioretinitis, etc.
• •4. Active intraocular inflammation (grade trace or above) in the study eye, or history of idiopathic or autoimmune-associated uveitis in either eye.
• •5. Uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥ 25 mmHg despite treatment with anti-glaucoma medication).
• •6. History of rhegmatogenous retinal detachment or macular hole (Stage 3 or 4) in the study eye.
• •7. Participation in a study of an investigational drug or device within 30 days prior to potential enrollment into the study.
• •8. Intraocular surgery (including cataract surgery) in the study eye within 60 days preceding baseline.
• •9. History of vitrectomy surgery in the study eye.
• •10. Subjects with 12 or more anti-VEGF injections within 24 months prior to Screening.
• •11. Subjects who received anti-VEGF therapy within 30 days of Screening or received steroid or laser therapy within 90 days of Screening.
• •12. Subjects allergic to fluorescein, povidone iodine (Betadyne) or aflibercept
• •13. Pregnant or breast-feeding women.